Lomitapide

BreastfeedingPediatric
  • TRADE NAME: Juxtapid (Aegerion)
  • INDICATIONS: Homozygous familial hypercholesterolemia
  • CLASS: Lipid regulator
  • HALF-LIFE: 39.7 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Bile acid sequestrants, Boceprevir, Clarithromycin, Conivaptan, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Lovastatin, Mibefradil, Nefazodone, Nelfinavir, Oral Contraceptives, P-glycoprotein substrates, Posaconazole, Ritonavir, Saquinavir, Simvastatin, Strong or moderate CYP3A4 inhibitors, Telaprevir, Telithromycin, Viloxazine, Voriconazole, Warfarin

PREGNANCY CATEGORY: X

BLACK BOX WARNING
RISK OF HEPATOTOXICITY

See full prescribing information for complete boxed warning.

Our database has 31 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of lomitapide in the Taylor & Francis journal Expert Opinion on Drug Safety. 

  (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 07/31/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top